Helperby Management Team

OUR TEAM COMBINES WORLD CLASS SCIENCE WITH INDUSTRY EXPERIENCE

We are a team of scientists, doctors, healthcare experts, and industry professionals dedicated to win the fight against deadly infectious diseases.

We are the inventors of an antibiotic renewal technology to overcome antibiotic resistant bacteria for many generations to come.

We are also using our platform to develop new combinations of old antimicrobials that we hope can cure the disease known as COVID-19.

Senior Management

James Phipson

Non executive Chairman and Director (Core Team)

Prof Anthony Coates

Founder & Chief Scientific Officer

Dr Yanmin Hu

Director Of Research

Erik van Kaathoven

Chief Financial Officer

Board & Advisors

Rashmi H Barbhaiya

Chair, Scientific Advisory Board

Mark J Goldberger

Member, Scientific Advisory Board

George L Drusano

Member, Scientific Advisory Board

Patrick Mocatta

Non-Executive Director (Core Team)

Dennis Molnar

Non-Executive Director (Core Team)

News

23 Mar 2020 • BBC reports Coronavirus continuing to develop globally

25 Jan 2020 • The Guardian Announces ‘Sepsis deaths around the world are twice as high as previously thought’.

21 Jul 2019 • Urinary Tract Infections Affect Millions. The Cures Are Faltering.

14 May 2019 • Antibiotic Combinations Could Be A Revolution In Fight Against Superbugs

14 May 2019 • Antibiotic Resistant Superbugs Creating Deadly Risks For Hip & Knee Operations

14 May 2019 • Take Over Pharma To Create New Medicines, Says Top Adviser

15 Feb 2019 • Antibiotic-Resistance-Plan-To-Fight-Urgent-Global-Threat

27 Jul 2018 • Develop New Antibiotics or Face Fines, Drug Firms Told

Key Papers

• Novel classes of antibiotics or more of the same?

• Novel approaches to developing new antibiotics for bacterial infections

• Can We Prevent Antimicrobial Resistance by Using Antimicrobials Better?

• Antibiotic Resistance - Global Response Needed

• Antimicrobial resistance characteristics and fitness of Gram-negative fecal bacteria from volunteers treated with minocycline or amoxicillin.

• Antibiotic Resistance Breakers: Revitalize Conventional Antibiotics. In: Novel Antimicrobial Agents and Strategies.